Answers are grounded in this paper and cite their sources.
per kg) RGX-111 for IV and IT routes of administration in MPS I mice, which prevented neurocognitive deficit, cardiac insufficiency, and skeletal manifestations, as a model for genetic therapy of human MPS I.
No takes yet. Share an insight, caveat, or question.
Belur et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: